- Delivers high-dose chemotherapy (typically FUDR/floxuridine) directly into the hepatic artery via an implanted pump
- Significant interest especially in the US (Memorial Sloan Kettering experience)
- Adjuvant HAIP post-resection associated with improved OS vs modern systemic chemotherapy alone
- Growing evidence for use in unresectable CRLM for conversion, particularly in patients refractory to systemic therapy
- Complications of:
- Hepatic artery thrombosis
- Biliary toxicity
- Incomplete perfusion of liver
- Misperfusion to the stomach or duodenum with ulcers